Cliff Bailey
Emeritus Professor, College of Health and Life Sciences | Aston University
Birmingham, UNITED KINGDOM
Professor Bailey's research is mainly directed towards the pathogenesis and treatment of diabetes.
Media
Publications:
Documents:
Photos:
Videos:
Audio/Podcasts:
Biography
Professor Bailey, PhD, FRCP(Edin), FRCPath is professor of clinical science in Life and Health Sciences at Aston University in Birmingham, UK, and fellow of both the Royal College of Physicians of Edinburgh of the Royal College of Pathologists.
He currently serves as senior editor of Diabetes and Vascuar Disease Research and has held editorial positions with the British Journal of Pharmacology; Diabetes, Obesity, and Metabolism; Lancet Diabetes Endocrinol, and Primary Care Diabetes. over the years.
He has been a Royal Society vising scientist at the University of Sourth Calironia in Los Angeles as well as a visiting scientist at Hanover Medical School in Germany.
He is also director of Biomedical Sciences Research in the Nutritional Biomedicine Research Group and a member of the research team in the Diabetes Research Group in the Aston University Research Centre for Healthy Ageing at Aston University.
He has published more than 400 research papers and reviews, as well as four textbooks, and has been honored with numerous awards including the Lunar Society Medal, the Banting Memorial Lecturer by the Diabetes UK, and the Royal Society of Biology Charter Lecturer.
Areas of Expertise (5)
Diabetes
Endocrinology
Insulin Therapy
Diabetes Treatments
Surrogate Beta-Cells
Accomplishments (11)
Aston University Anniversary Chair
2016
Royal Society of Biology Charter Lecturer
2015
Banting Memorial Lecturer
2015
Elsie Bertram Memorial Lecture, University of East Anglia
2014
Lunar Society Medal
2013
American Diabetes Association, State-of-the-Art Lecturer
2012
Fernandez-Cruz XXVII Memorial Symposium Lecturer
2008
St. Andrew’s Symposium Lecture, Royal College of Physicians, Edinburgh
2003
Howard Kolodny Lecture, Albert Einstein College of Medicine, New York
2001
Citations in Who’s Who in Science (USA), Who’s Who in Medicine (USA)
1996
Ciba Lecture prize in Clinical Biochemistry
1995
Affiliations (9)
- British Endocrine Society
- British Pharmacological Society
- Diabetes UK, Medical and Scientific Section
- Diabetes UK, Medical and Scientific Section
- European Association for the Study of Diabetes
- Founding Member of EASD Islet Study Group
- International Society of Diabetes & Vascular Disease
- Royal College of Pathologists
- Royal College of Physicians, Edinburg
Links (3)
Media Appearances (2)
Aston University professor named world expert in type 2 diabetes mellitus
Aston University News online
2021-11-12
Aston University professor emeritus, Cliff Bailey has been named as a world expert in type 2 diabetes mellitus by Expertscape, based on his research publications over the last ten years.
Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes
BusinessWire online
2012-11-15
Professor Clifford J Bailey Professor of Clinical Science, Life and Health Sciences University of Aston, UK
Articles (3)
864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED
Diabetes2022 In cardiovascular (CV) outcome trials (OT) of glucose-lowering medications (GLM) , glycated hemoglobin (A1c) is typically treated according to local standard of care, with aim of glycemic equipoise between the randomized groups. However, in SGLT inhibitor CVOTs, larger A1c reductions are consistently seen in the active therapy vs. placebo (PBO) groups, since the former has access to an additional class of GLM. SCORED was a multicenter, double-blind, placebo-controlled CVOT of the dual SGLT1 and 2 inhibitor sotagliflozin (SOTA) , which may have preserved antihyperglycemic effects even in those with advanced chronic kidney disease (CKD.) We assessed the association between A1c lowering and assignment to SOTA vs. PBO in the overall trial population and across various pre-specified subgroups, including CKD categories. 10,584 type 2 diabetes (T2D) (A1c ≥7%) patients with CKD (eGFR 25-60 mL/min/1.73 m2) and increased CV risk were randomized to SOTA vs. PBO and followed for a median of 15.9 months.
Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin
Frontiers in Pharmacology2022 Objectives: Pre-existing or new diabetes confers an adverse prognosis in people with Covid-19. We reviewed the clinical literature on clinical outcomes in metformin-treated subjects presenting with Covid-19. Methods: Structured PubMed search: metformin AND [covid (ti) OR covid-19 (ti) OR covid19 (ti) OR coronavirus (ti) OR SARS-Cov2 (ti)], supplemented with another PubMed search: “diabetes AND [covid OR covid-19 OR covid19 OR coronavirus (i) OR SARS-Cov2 (ti)]” (limited to “Clinical Study”, “Clinical Trial”, “Controlled Clinical Trial”, “Meta-Analysis”, “Observational Study”, “Randomized Controlled Trial”, “Systematic Review”). Results: The effects of metformin on the clinical course of Covid-19 were evaluated in retrospective analyses: most noted improved clinical outcomes amongst type 2 diabetes patients treated with metformin at the time of hospitalisation with Covid-19 infection.
Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure
Metabolism: Clinical and Experimental2022 Metformin has been in clinical use for the management of type 2 diabetes for more than 60 years and is supported by a vast database of clinical experience: this includes evidence for cardioprotection from randomised trials and real-world studies. Recently, the position of metformin as first choice glucose-lowering agent has been supplanted to some extent by the emergence of newer classes of antidiabetic therapy, namely the sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. These agents have benefitted through support from large cardiovascular outcomes trials with more modern trial designs than earlier studies conducted to assess metformin. Nevertheless, clinical research on metformin continues to further assess its many potentially advantageous effects. Here, we review the evidence for improved cardiovascular outcomes with metformin in the context of the current era of diabetes outcomes trials. Focus is directed towards the potentially cardioprotective actions of metformin in patients with type 2 diabetes and heart failure (HF), now recognised as the most common complication of diabetes.
Social